Literature DB >> 6449667

Histiocytosis-X.

M E Osband, J M Lipton, P Lavin, R Levey, G Vawter, J S Greenberger, R P McCaffrey, R Parkman.   

Abstract

Twelve of 17 patients with histiocytosis-X were immunologically abnormal, as shown by the presence of circulating lymphocytes spontaneously cytotoxic to cultured human fibroblasts or of antibody to autologous erythrocytes. The patients also had a notable lack of histamine H2 surface receptors on their T lymphocytes, suggesting a suppressor-cell deficiency. The lymphocyte abnormalities were reversed in vitro after incubation in a crude extract of calf thymus gland, and therefore all 17 patients were treated with daily intramuscular injections of this extract. With this therapy, 10 patients entered complete remission -- a response at least as good as that observed in historical controls treated with chemotherapy. A positive clinical response was associated with an increase in the number of T-cell histamine H2 receptors to normal levels and with correction of the other immunologic abnormalities. The results of this preliminary study justify a larger prospective clinical trial of thymic extract and further investigation of the immunoregulatory mechanisms in histiocytosis-X.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6449667     DOI: 10.1056/NEJM198101153040304

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  24 in total

1.  The variable presentation and natural history of Langerhans cell histiocytosis.

Authors:  J A Buckwalter; E Brandser; R A Robinson
Journal:  Iowa Orthop J       Date:  1999

2.  Genital ulceration in a 4 year old--a case of safeguarding? From social services to pathology...

Authors:  Emma Roche; Nikila Pandya; Lamios Munthali; Ayad Atra
Journal:  BMJ Case Rep       Date:  2012-06-21

Review 3.  Interferon-alpha in childhood haematological malignancies.

Authors:  R Simkó; K Nagy
Journal:  Postgrad Med J       Date:  1996-12       Impact factor: 2.401

Review 4.  Histiocytic syndromes.

Authors:  L Corbeel
Journal:  Eur J Pediatr       Date:  1988-10       Impact factor: 3.183

5.  Suppressor-cell dysfunction in children with histiocytosis-X.

Authors:  B T Shannon; W A Newton
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

6.  Circulating thymic hormone activity in young cancer patients.

Authors:  R Consolini; B Cei; P Cini; E Bottone; L Casarosa
Journal:  Clin Exp Immunol       Date:  1986-10       Impact factor: 4.330

7.  Pulmonary histiocytosis X.

Authors:  T W Marcy; H Y Reynolds
Journal:  Lung       Date:  1985       Impact factor: 2.584

8.  Histiocytosis X--current controversies.

Authors:  V Broadbent; J Pritchard
Journal:  Arch Dis Child       Date:  1985-07       Impact factor: 3.791

9.  Spontaneous healing of Langerhans cell histiocytosis (histiocytosis X).

Authors:  L Corbeel; E Eggermont; J Desmyter; I Surmont; R De Vos; C De Wolf-Peeters; C Cobbaert; A Eykens
Journal:  Eur J Pediatr       Date:  1988-10       Impact factor: 3.183

10.  Controlled trial of a thymic hormone extract (Thymostimulin) in 'autoimmune' chronic active hepatitis.

Authors:  J E Hegarty; K T Nouri Aria; A L Eddleston; R Williams
Journal:  Gut       Date:  1984-03       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.